These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 3881051)

  • 21. Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
    Jenike MA; Albert MS; Baer L
    Alzheimer Dis Assoc Disord; 1990; 4(4):226-31. PubMed ID: 2264980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pilot study of clonidine plus physostigmine in Alzheimer's disease.
    Bierer LM; Aisen PS; Davidson M; Ryan TM; Schmeidler J; Davis KL
    Dementia; 1994; 5(5):243-6. PubMed ID: 7951680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral physostigmine and lecithin improve memory in Alzheimer disease.
    Thal LJ; Fuld PA; Masur DM; Sharpless NS
    Ann Neurol; 1983 May; 13(5):491-6. PubMed ID: 6347034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
    Harrell LE; Jope RS; Falgout J; Callaway R; Avery C; Spiers M; Leli D; Morere D; Halsey JH
    J Am Geriatr Soc; 1990 Feb; 38(2):113-22. PubMed ID: 2405043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.
    Cain JW
    Am J Psychiatry; 1986 Jul; 143(7):910-2. PubMed ID: 3717434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
    Beller SA; Overall JE; Swann AC
    Psychopharmacology (Berl); 1985; 87(2):147-51. PubMed ID: 3931138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral physostigmine as treatment for primary degenerative dementia: a double-blind placebo-controlled inpatient trial.
    Jenike MA; Albert M; Baer L; Gunther J
    J Geriatr Psychiatry Neurol; 1990; 3(1):13-6. PubMed ID: 2189429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
    Marin DB; Bierer LM; Lawlor BA; Ryan TM; Jacobson R; Schmeidler J; Mohs RC; Davis KL
    Psychiatry Res; 1995 Oct; 58(3):181-9. PubMed ID: 8570774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
    Canal N; Imbimbo BP
    Clin Pharmacol Ther; 1996 Aug; 60(2):218-28. PubMed ID: 8823240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of long-term physostigmine administration in Alzheimer's disease.
    Harrell LE; Callaway R; Morere D; Falgout J
    Neurology; 1990 Sep; 40(9):1350-4. PubMed ID: 2392216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
    Peskind ER; Wingerson D; Pascualy M; Thal L; Veith RC; Dorsa DM; Bodenheimer S; Raskind MA
    Biol Psychiatry; 1995 Oct; 38(8):532-8. PubMed ID: 8562665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward an effective treatment of Alzheimer's disease.
    Blass JP; Weksler ME
    Ann Intern Med; 1983 Feb; 98(2):251-3. PubMed ID: 6824261
    [No Abstract]   [Full Text] [Related]  

  • 33. Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
    Davidson M; Bierer LM; Kaminsky R; Ryan TM; Davis KL
    Alzheimer Dis Assoc Disord; 1989; 3(4):224-7. PubMed ID: 2688700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physostigmine ameliorates the delusions of Alzheimer's disease.
    Cummings JL; Gorman DG; Shapira J
    Biol Psychiatry; 1993 Apr; 33(7):536-41. PubMed ID: 8513039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
    Sunderland T; Molchan S; Lawlor B; Martinez R; Mellow A; Martinson H; Putnam K; Lalonde F
    Int Psychogeriatr; 1992; 4 Suppl 2():291-309. PubMed ID: 1288668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.
    Caltagirone C; Gainotti G; Masullo C
    Int J Neurosci; 1982 May; 16(3-4):247-9. PubMed ID: 7169287
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender.
    Peskind ER; Raskind MA; Wingerson D; Pascualy M; Thal LJ; Dobie DJ; Wilkinson CW
    Biol Psychiatry; 1996 Jul; 40(1):61-8. PubMed ID: 8780856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of physostigmine and lecithin on memory in Alzheimer disease.
    Peters BH; Levin HS
    Ann Neurol; 1979 Sep; 6(3):219-21. PubMed ID: 534419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observations on the physostigmine syndrome in patients with Alzheimer's disease.
    Wirkowski E; Prohovnik I; Young WL
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):73-5. PubMed ID: 7580177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.